SCM
FOMX

Stonepine Capital Management’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History

Stonepine Capital Management’s Portfolio FOMX Stock Details FOMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-651,211
Closed -$1.55M – 32
2019
Q2 		$1.55M Sell
651,211
-78,793
-11% -$235K 1.07% 19
2019
Q1 		$2.74M Sell
730,004
-563,173
-44% -$2.11M 1.57% 19
2018
Q4 		$4.64M Buy
1,293,177
+742,099
+135% +$3.23M 4.08% 12
2018
Q3 		$3.16M Buy
+551,078
New +$3.15M 1.85% 16
2018
Q2 		– Sell
-129,756
Closed -$666K – 35
2018
Q1 		$666K Buy
+129,756
New +$781K 0.36% 25
2017
Q3 		– Sell
-2,878
Closed -$13K – 29
2017
Q2 		$13K Buy
+2,878
New +$12.8K 0.01% 27

Other funds holding FOMX

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
SM
Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DAM
DLD Asset Management New York $1.51B AUM 5.32% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Stonepine Capital Management's FOMX Position: Q3 2019 in Review

Stonepine Capital Management sold out of Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) in Q3 2019, closing a stake of 651,211 shares — an estimated $1.55M sold.

Stonepine Capital Management first reported a position in FOMX in Q2 2017 and held it in 6 quarters. The position peaked at $4.64M in Q4 2018. 59 funds tracked by Wall St. Rank hold FOMX as of Q3 2019.

  • Stonepine Capital Management reported no remaining Foamix Pharmaceuticals Ltd. Ordinary Shares position as of Q3 2019 after selling out during the quarter.
  • Stonepine Capital Management sold 651,211 Foamix Pharmaceuticals Ltd. Ordinary Shares shares in Q3 2019, an estimated $1.55M.
  • Stonepine Capital Management first reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares in Q2 2017 and held it in 6 quarters.
  • Stonepine Capital Management's Foamix Pharmaceuticals Ltd. Ordinary Shares position peaked at $4.64M in Q4 2018.
  • 59 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q3 2019.

Based on Stonepine Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.